Tumor-initiated mice were treated with anti-PD-1 alone, a combination of cisplatin and anti-PD-1 or DCP-IL-12/FLT3L with cisplatin and anti-PD-1 (Fig. 6m). This evidence concerns the gene FLT3LG and neoplasm.